Biomaterial-assisted Neoantigen Cancer Vaccines
Creative Biolabs, with more than a decade of vaccine development history, has evolved into a benchmark and leader in the industry. Our business is now deployed in the development of various disease vaccines, we can provide a full range of technical support and services, including development, production, and evaluation of bacterial, viral and other infectious disease vaccines and cancer vaccines.
Background
In the past, cancer vaccines were generally tumor-associated antigens that were highly expressed in tumor cells and underexpressed in normal cells or tissues. One of the advantages of this kind of antigens is that they can be used as a universal target for patients with the same type of malignancy. However, the problem is that a vaccine targeting this antigen may cause immune tolerance and cause a decrease in vaccination efficiency or cause an autoimmune response against normal tissues. The discovery of neoantigen made it possible to develop safe and effective individualized vaccines. Cancer vaccines developed using the neoantigen that exclusively expressed on tumor cells from tumor genome mutations have also been shown in clinical trials to elicit a strong neoantigen-specific T cell response in advanced melanoma patients. These gratifying results have spurred researchers to develop a passion for neoantigen-based cancer vaccines.
Biomaterial-assisted Neoantigen Cancer Vaccines
The presentation of antigens to antigen-presenting cells (APCs) is an important step in exerting efficacy of vaccines and is, therefore, an issue that must be considered when designing vaccines. The use of biological materials to deliver neoantigen cancer vaccines is a new and promising concept, although biomaterials have been widely used in the delivery of vaccines due to their ability to protect antigens and adjuvant molecules. Polymer-based nanoparticle vaccines could deliver vaccines to the cytosol in an acidic environment of endosomes for efficient presentation. Highly safe, scalable synthetic high-density lipoprotein nanomaterials can also be used to deliver neoantigen to prolong antigen presentation and enhance immune response. In addition, biomaterials are also designed to achieve passive delivery of antigens in vivo by capturing antigens. The experimental results show that intra-tumor injection of poly(lactic-co-glycolic acid) nanoparticles can capture tumor antigens including neoantigens, promoting their internalization and antigen presentation. Bulk biomaterials can also enhance the presentation of tumor vaccines by constructing artificial antigen-presenting niche (which can recruit dendritic cells for capturing and presenting antigens) in vivo.
Our Services for Development of Biomaterial-assisted Neoantigen Cancer Vaccines
- Neoantigen or neoepitope prediction
- Design and preparation of various of biomaterial-based neoantigen cancer vaccine
- Development of vaccine formula
- Evaluation of efficacy and safety profiles of vaccine candidate
With more than a decade of vaccine development history, Creative Biolabs has accumulated a lot of successful experience and has won high praise from many customers. We have a professional vaccine development team that can help clients develop safe and effective vaccines in a variety of disease areas. If you have any need for vaccine development, please contact us immediately!
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
